Nucleic Acid Therapeutics Market Size, Share, and Trends 2024 to 2034

The global nucleic acid therapeutics market size is calculated at USD 6.44 billion in 2025 and is forecasted to reach around USD 17.02 billion by 2034, accelerating at a CAGR of 11.42% from 2025 to 2034. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.

  • Last Updated : February 2025
  • Report Code : 4385
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Nucleic Acid Therapeutics Market 

5.1. COVID-19 Landscape: Nucleic Acid Therapeutics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Nucleic Acid Therapeutics Market, By Products

8.1. Nucleic Acid Therapeutics Market Revenue and Volume, by Products

8.1.1 Anti-sense Oligonucleotides (ASOs) and DNA Aptamers

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. RNA Interference [RNAi] and Short Interfering RNAs [siRNAs]

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Others

8.1.3.1. Market Revenue and Volume Forecast

Chapter 9. Global Nucleic Acid Therapeutics Market, By Application

9.1. Nucleic Acid Therapeutics Market Revenue and Volume, by Application

9.1.1. Monogenetic Disorders

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Multi-Genetic Disorders

9.1.2.1. Market Revenue and Volume Forecast

Chapter 10. Global Nucleic Acid Therapeutics Market, By End User 

10.1. Nucleic Acid Therapeutics Market Revenue and Volume, by End User

10.1.1. Hospitals and Clinics

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Academic and Research Institutes

10.1.2.1. Market Revenue and Volume Forecast

Chapter 11. Global Nucleic Acid Therapeutics Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Volume Forecast, by Products

11.1.2. Market Revenue and Volume Forecast, by Application

11.1.3. Market Revenue and Volume Forecast, by End User

11.1.4. U.S.

11.1.4.1. Market Revenue and Volume Forecast, by Products

11.1.4.2. Market Revenue and Volume Forecast, by Application

11.1.4.3. Market Revenue and Volume Forecast, by End User

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Volume Forecast, by Products

11.1.5.2. Market Revenue and Volume Forecast, by Application

11.1.5.3. Market Revenue and Volume Forecast, by End User

11.2. Europe

11.2.1. Market Revenue and Volume Forecast, by Products

11.2.2. Market Revenue and Volume Forecast, by Application

11.2.3. Market Revenue and Volume Forecast, by End User

11.2.4. UK

11.2.4.1. Market Revenue and Volume Forecast, by Products

11.2.4.2. Market Revenue and Volume Forecast, by Application

11.2.4.3. Market Revenue and Volume Forecast, by End User

11.2.5. Germany

11.2.5.1. Market Revenue and Volume Forecast, by Products

11.2.5.2. Market Revenue and Volume Forecast, by Application

11.2.5.3. Market Revenue and Volume Forecast, by End User

11.2.6. France

11.2.6.1. Market Revenue and Volume Forecast, by Products

11.2.6.2. Market Revenue and Volume Forecast, by Application

11.2.6.3. Market Revenue and Volume Forecast, by End User

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Volume Forecast, by Products

11.2.7.2. Market Revenue and Volume Forecast, by Application

11.2.7.3. Market Revenue and Volume Forecast, by End User

11.3. APAC

11.3.1. Market Revenue and Volume Forecast, by Products

11.3.2. Market Revenue and Volume Forecast, by Application

11.3.3. Market Revenue and Volume Forecast, by End User

11.3.4. India

11.3.4.1. Market Revenue and Volume Forecast, by Products

11.3.4.2. Market Revenue and Volume Forecast, by Application

11.3.4.3. Market Revenue and Volume Forecast, by End User

11.3.5. China

11.3.5.1. Market Revenue and Volume Forecast, by Products

11.3.5.2. Market Revenue and Volume Forecast, by Application

11.3.5.3. Market Revenue and Volume Forecast, by End User

11.3.6. Japan

11.3.6.1. Market Revenue and Volume Forecast, by Products

11.3.6.2. Market Revenue and Volume Forecast, by Application

11.3.6.3. Market Revenue and Volume Forecast, by End User

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Volume Forecast, by Products

11.3.7.2. Market Revenue and Volume Forecast, by Application

11.3.7.3. Market Revenue and Volume Forecast, by End User

11.4. MEA

11.4.1. Market Revenue and Volume Forecast, by Products

11.4.2. Market Revenue and Volume Forecast, by Application

11.4.3. Market Revenue and Volume Forecast, by End User

11.4.4. GCC

11.4.4.1. Market Revenue and Volume Forecast, by Products

11.4.4.2. Market Revenue and Volume Forecast, by Application

11.4.4.3. Market Revenue and Volume Forecast, by End User

11.4.5. North Africa

11.4.5.1. Market Revenue and Volume Forecast, by Products

11.4.5.2. Market Revenue and Volume Forecast, by Application

11.4.5.3. Market Revenue and Volume Forecast, by End User

11.4.6. South Africa

11.4.6.1. Market Revenue and Volume Forecast, by Products

11.4.6.2. Market Revenue and Volume Forecast, by Application

11.4.6.3. Market Revenue and Volume Forecast, by End User

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Volume Forecast, by Products

11.4.7.2. Market Revenue and Volume Forecast, by Application

11.4.7.3. Market Revenue and Volume Forecast, by End User

11.5. Latin America

11.5.1. Market Revenue and Volume Forecast, by Products

11.5.2. Market Revenue and Volume Forecast, by Application

11.5.3. Market Revenue and Volume Forecast, by End User

11.5.4. Brazil

11.5.4.1. Market Revenue and Volume Forecast, by Products

11.5.4.2. Market Revenue and Volume Forecast, by Application

11.5.4.3. Market Revenue and Volume Forecast, by End User

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Volume Forecast, by Products

11.5.5.2. Market Revenue and Volume Forecast, by Application

11.5.5.3. Market Revenue and Volume Forecast, by End User

Chapter 12. Company Profiles

12.1. Genzyme

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Sanofi

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Piezo Therapeutics

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Transcode Therapeutics

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. NOVARTIS AG.

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Aldevron

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Switch Therapeutics

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Sarpeta Therapeutics

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Qaigen NV

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Impilo Therapeutics

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global nucleic acid therapeutics market size is expected to increase USD 17.02 billion by 2034 from USD 5.77 billion in 2024.

The global nucleic acid therapeutics market will register growth rate of 11.42% between 2025 and 2034.

The major players operating in the nucleic acid therapeutics market are Genzyme, Sanofi, Piezo Therapeutics, Transcode Therapeutics, NOVARTIS AG., Aldevron, Switch Therapeutics, Sarpeta Therapeutics, Qaigen NV, Impilo Therapeutics, Protagonist Therapeutics, Copernicus, Benitec Biopharma, Silence Therapeutics, Arbutus Biopharma, Thermo Fisher Scientific, Merck KGaA, Agilent Technologies, and Others.

The driving factors of the nucleic acid therapeutics market are the growing number of chronic and genetic diseases and growing advancements in medical sciences and biotechnology.

North America region will lead the global nucleic acid therapeutics market during the forecast period 2025 to 2034.

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client